News for 'GSK India'

How HUL and P&G are shaping their India strategy

How HUL and P&G are shaping their India strategy

Rediff.com23 Dec 2019

While Unilever has been aggressive, both organically and inorganically in the country, P&G's approach has been about achieving 'balanced growth' in terms of top line and bottom line.

Serum, Bharat Biotech halt Covid vaccine production as demand slips

Serum, Bharat Biotech halt Covid vaccine production as demand slips

Rediff.com4 Apr 2022

Sources indicated that there were no fresh orders from the Government of India, and their supply commitments have ended as of March 31, reports Sohini Das.

How Amway grew bigger than Procter & Gamble, Gillette in India

How Amway grew bigger than Procter & Gamble, Gillette in India

Rediff.com29 May 2013

Amway surged by converting a multitude into sales agents.

Now, Pfizer, Novartis, GSK under USFDA scanner

Now, Pfizer, Novartis, GSK under USFDA scanner

Rediff.com19 Jul 2008

Amid reports of a US Congress probe against India's largest drug maker Ranbaxy Laboratories, data show that many leading multinational companies such as Pfizer, GlaxoSmithKline, Novartis and Merck are also under the scanner of the US drug regulator, for more or less similar violations as Ranbaxy is alleged to have committed.

What lies ahead for Brand Horlicks?

What lies ahead for Brand Horlicks?

Rediff.com11 Dec 2018

One of the oldest living brands in the country, Horlicks has been innovative in its approach, which helped it survive intense competition

MNC pharma cos may be afflicted by pneumonia virus

MNC pharma cos may be afflicted by pneumonia virus

Rediff.com22 Apr 2019

Aurobindo Pharma, Cadila Healthcare and Serum Institute are readying their vaccine candidates.

Serum Inst to launch first indigenous vaccine against pneumonia

Serum Inst to launch first indigenous vaccine against pneumonia

Rediff.com24 Dec 2020

According to the sources, the vaccine will be much more affordable than existing ones manufactured by two foreign companies. India's drug regulator in July had granted market approval for the Pneumococcal Polysaccharide Conjugate vaccine, after reviewing the phase 1, 2 and 3 clinical trial data submitted by the Pune-based firm.

How US companies are helping India fight coronavirus

How US companies are helping India fight coronavirus

Rediff.com16 Apr 2020

A large number of American companies like Google, Uber and IBM are offering their resources to help India successfully fight the battle against the deadly coronavirus pandemic.

Govt clears GlaxoSmithKline's Rs 6,400-crore FDI proposal

Govt clears GlaxoSmithKline's Rs 6,400-crore FDI proposal

Rediff.com20 Feb 2014

The Cabinet Committee on Economic Affairs has approved the proposal of GlaxoSmithKline Pte Limited, Singapore for acquisition of 24.33 per cent shares in existing Indian subsidiary company of GSK Group.

2018: Year of reckoning for India Inc

2018: Year of reckoning for India Inc

Rediff.com28 Dec 2018

A glance back at some of the important ups and down Indian Inc faced in 2018.

'India's patent policy is discouraging innovation'

'India's patent policy is discouraging innovation'

Rediff.com30 Mar 2010

US-based Eli Lilly has planned to continue its focus on innovation-driven products, instead of opening up to opportunities in off-patent generic drugs, being tapped by its larger competitors like GSK and Pfizer.

Taapsee, Madhavan and the remaking of an old favourite

Taapsee, Madhavan and the remaking of an old favourite

Rediff.com21 Mar 2018

Horlicks widens brand appeal in increasingly competitive market.

India Inc gets back to office cautiously, even as many MNCs remain shut

India Inc gets back to office cautiously, even as many MNCs remain shut

Rediff.com21 Jan 2021

Many are testing hybrid models including getting small batches to work, rotating staff every week, introducing shifts and allowing certain functions to operate from office in small numbers.

Dr Reddy's Q1 Net up 52.49% at Rs 550 cr

Dr Reddy's Q1 Net up 52.49% at Rs 550 cr

Rediff.com30 Jul 2014

DRL launched four new products in North America during the previous quarter.

How Kohli's absence in Asia Cup hits Star India's plans

How Kohli's absence in Asia Cup hits Star India's plans

Rediff.com18 Sep 2018

While it is difficult to put a number on how much the impact on the ad sales tally could be, it is quite possible the broadcaster will not be able to make its Rs 2-billion target, says Urvi Malvania.

This path-breaking vaccine may win a Nobel, and it's for not Covid

This path-breaking vaccine may win a Nobel, and it's for not Covid

Rediff.com20 Oct 2021

The new malaria vaccine (RTS.S/ AS01, tentatively brand-named Mosquirix) is the very first one to offer immunity against a parasite -- specifically the plasmodium falciparum parasite, which is the deadliest of the five parasites that cause malaria.

FMCG leaders beat FY21 blues, exceed pre-Covid levels

FMCG leaders beat FY21 blues, exceed pre-Covid levels

Rediff.com5 Aug 2021

In spite of a severe second wave of the coronavirus pandemic, and a widespread disruption in public life therefore, India's fast-moving consumer goods (FMGC) sector seems to have emerged as one of the most resilient segments of the economy. The early numbers and estimates for the April-June quarter indicate a steady recovery in FMCG players' business, which is now set to exceed the pre-pandemic level. Amid nationwide lockdowns because of the first Covid wave, FMCG revenues had been severely affected in mid-2020.

FIPB clears GlaxoSmithKline's Rs 6,400-crore FDI proposal

FIPB clears GlaxoSmithKline's Rs 6,400-crore FDI proposal

Rediff.com13 Jan 2014

The Singapore subsidiary of the UK-based GlaxoSmithKline plans to buy 24.33 per cent stake or 2.06 crore equity shares in GlaxoSmithKline Pharmaceuticals Ltd through an open offer.

Pharma MNCs' pills make Indian rivals sick

Pharma MNCs' pills make Indian rivals sick

Rediff.com19 Oct 2011

Severe price cuts help multinationals ramp up growth, gain market share.

Biological E plans to make 1.5 billion Corbevax jabs in 2021

Biological E plans to make 1.5 billion Corbevax jabs in 2021

Rediff.com2 Jul 2021

By 2022, there is a plan to make an mRNA-technology vaccine, for which it has tied up with Canadian firm Providence Therapeutics.

Sindhu & Gopichand lure India towards sport drinks

Sindhu & Gopichand lure India towards sport drinks

Rediff.com10 Oct 2017

With a new campaign for Gatorade and renewed thrust on sports drinks, PepsiCo looks to make the most of the growing passion for fitness in the country.

'Our Indian operations are a great success story'

'Our Indian operations are a great success story'

Rediff.com10 Mar 2010

Andrew Witty, chief executive of GlaxoSmithKline (GSK), the world's second-largest drug company, was in India this week as part of the dedication of an albandazole manufacturing facility at Nashik to the World Health Organization (WHO)'s global programme to eliminate Lymphatic Filariasis.

Glaxo interested in Indian acquisitions

Glaxo interested in Indian acquisitions

Rediff.com9 Mar 2010

GlaxoSmithKline, the world's second biggest drug maker, said it was interested in acquisitions in India if the assets came at the right value.

Glaxo sets teeth on dental opening

Glaxo sets teeth on dental opening

Rediff.com6 Jan 2011

With the expectation of a big rise in the market for 'sensitive toothpastes' in the near term, GlaxoSmithKline (GSK), the largest company in the health food sector, has forayed into this category in India with its biggest global brand, Sensodyne Toothpaste. This has been launched across all metropolitan and Tier-I cities.

4 brands that hit Rs 100-crore mark in record time

4 brands that hit Rs 100-crore mark in record time

Rediff.com18 Jul 2016

Bubbly is the latest in a string of brands that are touching the three-digit mark quickly.

Despite green shoots, consumer goods companies on slippery road

Despite green shoots, consumer goods companies on slippery road

Rediff.com23 May 2018

The biggest challenge is crude oil's sustained rally - it is nearing $80 a barrel - stoking inflationary pressures and consequent price hikes in the sector.

India Inc's growing disconnect between profits and dividends

India Inc's growing disconnect between profits and dividends

Rediff.com12 Dec 2014

Some big ones hoard cash unduly and others borrow to keep up payments to shareholders

FSSAI proposes double ash content in noodles

FSSAI proposes double ash content in noodles

Rediff.com13 Jul 2016

Ash content is now allowed up to 1%, the new notification has proposed to increase it to 2% for seasonings or tastemakers.

ITC pushes Yippee noodles to replace Maggi

ITC pushes Yippee noodles to replace Maggi

Rediff.com13 Jun 2015

ITC has provided retailers with leaflets to assure customers of Yippee noodle's quality and safety standards

Flu drug plans take a hit

Flu drug plans take a hit

Rediff.com17 Nov 2005

Glaxo to roll out 7 vaccines

Glaxo to roll out 7 vaccines

Rediff.com16 Oct 2004

Glaxo, Burroughs swap ratio at 14:10

Glaxo, Burroughs swap ratio at 14:10

Rediff.com17 Mar 2004

The much-awaited merger of Burroughs Wellcome India Ltd with GlaxoSmithKline Pharmaceuticals Ltd in the country was approved by boards of both entities on Wednesday with a swap ratio of 14:10 shares.

Rupee crash: MNCs advised to raise stakes in Indian arms

Rupee crash: MNCs advised to raise stakes in Indian arms

Rediff.com11 Jun 2013

Some investment bankers expect the Indian currency to touch 60-65 by the end of the year

Promoter stake in listed firms at 16-year low

Promoter stake in listed firms at 16-year low

Rediff.com8 Aug 2017

For the first time since 2001, promoter stake in BSE 500 decisively below 50%

Cipla bets big on consumer health segment

Cipla bets big on consumer health segment

Rediff.com25 Apr 2016

Company aims to build five Rs 100 cr-plus brands and launch products from South African arm in domestic market

ITC goes in for more tests of its products

ITC goes in for more tests of its products

Rediff.com8 Jun 2015

ITC on Monday said it is conducting more tests on its products at accredited labs across India.

From social media influencers to #metoo, 2018 was a 'brand' new year

From social media influencers to #metoo, 2018 was a 'brand' new year

Rediff.com29 Dec 2018

What sets 2018 apart from previous years is the magnitude of the shocks that hit our brand ecosystem, says Bharat Bambawale.